Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.03.20	Karolinska Development Annual Report 2019 published (GlobeNewswire)
16.03.20	Karolinska Development changes date for the Annual General Meeting (GlobeNewswire)
09.03.20	Karolinska Development appoints Johan Dighed as General Counsel (GlobeNewswire)
13.02.20	Year-End Report - January-December 2019 (GlobeNewswire)
30.01.20	Karolinska Development's portfolio company Aprea Therapeutics receives FDA Breakthrough Therapy Designation (GlobeNewswire)
09.01.20	Karolinska Development has repaid the remaining part of the company's convertible loan (GlobeNewswire)
30.12.19	Change of number of shares and votes in Karolinska Development (GlobeNewswire)
20.12.19	Karolinska Development´s portfolio company Umecrine Cognition announces Notice of Allowance from USPTO for a patent protecting lead compound golexanolone (GlobeNewswire)
19.12.19	Karolinska Development has secured its short-term financing needs (GlobeNewswire)
18.12.19	Karolinska Development announces the final result of the directed share issue to the Company's convertible loan holders (GlobeNewswire)
13.12.19	Karolinska Development publishes an update on the net profit effect of the portfolio company Aprea Therapeutics share price development and a prospectus supplement relating to the directed share issue (GlobeNewswire)
13.12.19	Karolinska Development´s portfolio company Umecrine Cognition completes enrollment to phase 2a study in liver cirrhosis and hepatic encephalopaty (GlobeNewswire)
12.12.19	Acquirer of SEK 121 million of convertible loan in Karolinska Development commits to set-off and the subscription period in the directed share issue is extended (GlobeNewswire)
11.12.19	Karolinska Development’s portfolio company Forendo Pharma enters license and collaboration agreement with leading pharma company (GlobeNewswire)
09.12.19	Karolinska Development´s portfolio company Aprea Therapeutics presents data from two Phase Ib/II studies of APR-246 at the American Society of Hematology meeting (GlobeNewswire)
29.11.19	Change of number of shares and votes in Karolinska Development (GlobeNewswire)
29.11.19	Interim Report January - September 2019 (GlobeNewswire)
20.11.19	Karolinska Development announces the result of the first partial registration in the directed share issue to the Company's convertible loan holders (GlobeNewswire)
07.11.19	Karolinska Development’s portfolio company OssDsign reports favourable outcome data on OSSDSIGN Cranial PSI (GlobeNewswire)
06.11.19	Karolinska Development publishes prospectus supplement relating to the directed share issue to the Company’s convertible holders (GlobeNewswire)
06.11.19	Holders of Karolinska Development’s convertible loan have agreed to set-off and repurchase 94 per cent of outstanding convertibles (GlobeNewswire)
05.11.19	New date for publication of Karolinska Developments Interim Report January – September 2019 (GlobeNewswire)
28.10.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
28.10.19	Karolinska Development divests its ownership in Asarina Pharma (GlobeNewswire)
14.10.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
14.10.19	Karolinska Development’s portfolio company OssDsign receives US FDA clearance for Cranial PSI Accessories (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten